Skip to content

Advertisement

Annals of Intensive Care

Annals of Intensive Care Cover Image
  • Research
  • Open Access

Effect of HA330 resin-directed hemoadsorption on a porcine acute respiratory distress syndrome model

  • †1, 2,
  • †3,
  • 3,
  • 1, 4,
  • 1, 5,
  • 3 and
  • 1, 3Email author
†Contributed equally
Annals of Intensive Care20177:84

https://doi.org/10.1186/s13613-017-0287-0

©  The Author(s) 2017

Received: 15 November 2016

Accepted: 2 June 2017

Published: 14 August 2017

Abstract

Background

Blood purification is an emerging approach to dampening the cytokine storm. This study aims to assess the efficacy of HA330 resin-directed hemoadsorption (HA) on endotoxin-induced porcine acute respiratory distress syndrome (ARDS) model.

Methods

Twenty-four Chinese domestic pigs were allocated into saline group receiving intravenous infusion of saline (N = 6) and endotoxin group receiving intravenous infusion of LPS (N = 18). When ALI model was initially diagnosed, six pigs in the LPS and saline group were killed for BALF and histopathological analysis. The remaining 12 pigs in LPS group received 3-h HA (N = 6) or HA-sham (N = 6) treatment, respectively. Following another 5-h observation, animals were killed. Variables on hemodynamics, blood gases and lung mechanics were recorded at a series of time points. Differentially expressed cytokines and proteins were determined by ELISA and proteomics.

Results

HA treatment significantly improved injured oxygenation induced by LPS. HA also partially improved the barrier permeability and reduced lung edema and inflammation/injury induced by LPS infusion. Proteomic analysis showed the differentially expressed proteins between HA- and HA-sham-treated groups mostly belonged to the categories of acute inflammation/immune response, and proteolysis.

Conclusions

Hemoadsorption improved ARDS possibly by blunting the cytokine storm and by restoring homeostasis of the disordered proteome milieu in the exudative phase.

Keywords

  • ARDS
  • Cytokine storm
  • Hemoadsorption
  • Porcine model
  • Proteomics

Background

The acute respiratory distress syndrome (ARDS) is a condition with the acute onset of noncardiac respiratory failure that develops in response to a series of insults to the alveolar-capillary barrier [1]. The current mainstay therapy for ARDS is largely supportive [2, 3]. This has been shown to reduce mortality by limiting further iatrogenic injury to the already injured lungs. However, the mortality rate of ARDS is still unacceptably high [4]. ARDS is largely caused by the local alveolar and circulating “cytokine storm” that happens with bacterial/virus infection, burn/trauma and some possible iatrogenic factors, such as high-volume ventilation [5]. This has encouraged the development of several specific targeted pharmacologic therapy directed against single key pathogenic mediators. However, most clinical trials have proven no benefit to disease outcome and were stopped early for futility [6]. Investigators shifted their interests into the extracorporeal blood purification (EBP) modality, which is a nonspecific, broad-spectrum method to blunt the “cytokine storm” by immediately clearing a series of circulating and resident mediators [7].

Until now, there are only some inconsistent preliminary data to investigate the effects of hemofiltration (a modality of EBP) on ARDS animal models [8, 9]. Also, it has been shown that hemoadsorption (HA), another modality of EBP, can improve oxygenation in septic patients [10, 11]. However, evidences of HA’s effects on ARDS patients animal models are scarce. We hypothesize that HA can improve oxygenation, reduce the permeability of alveolar-capillary barrier and alleviate pulmonary edema/damage by blunting the circulating/alveolar cytokines in the process of ARDS. To test this hypothesis, we established an endotoxin-induced ARDS porcine model to explore HA’s therapeutic effect by using a HA330 resin cartridge (a new weapon against cytokine storm).

Methods

Research animals and ethical considerations

This study was approved by the Institutional Animal Experiment Committee of Beijing Hospital. All experiments were performed according to the Declaration of Helsinki conventions for the use and care of animals. Twenty-four healthy, 3–4-week-old Chinese domestic white pigs of both sexes were chosen from a local stock routinely used for the experimental research. The average weight of pigs used in this experimental procedure is 43 ± 0.3 kg (mean ± SEM).

Animal preparations

Sedation, anesthesia and muscle relaxation

Detailed information is shown in Additional file 1: Supplement-Methods.

Ventilation and measurements of lung mechanics

Animals were ventilated in a volume-controlled mode. The ventilation protocol at baseline used a tidal volume of 10 ml/kg body weight, a fraction of inspired oxygen (FiO2) of 0.4 and a positive end-expiratory pressure (PEEP) at 0 cmH2O. Parameters of lung mechanics were recorded. Detailed information is shown in Additional file 1: Supplement-Methods.

Instrumentation and hemodynamic measurements

Cardiac output (CO), mean arterial pressure (MAP), systematic vascular resistance (SVR), mean pulmonary arterial pressure (MPAP), pulmonary vascular resistance (PVR), pulmonary artery wedge pressure (PAWP), extravascular lung water (EVLW) and pulmonary vascular permeability index (PVPI) were measured with PiCCO and Swan-Ganz systems. Detailed information is shown in Additional file 1: Supplement-Methods.

Experimental protocol

After surgical preparations and instrumentation, all animals were ventilated in prone position and a period of 1 h was left for animal stabilization. Thereafter, baseline (i.e., the time point after 1-h stabilization) parameters including lung mechanics, hemodynamics, blood gases were recorded and venous blood samples were collected. As a next step, lung injury model was produced with i.v. infusion of 50 μg/kg LPS (Escherichia coli, serotype O55:B5, Sigma-Aldrich, St. Louis, MO, USA) mixed in 500 ml of saline that was delivered via a volumetric infusion pump (Instrumentation Laboratory, Bedford, MA, USA) for about 2 h [12, 13]. Before the start of the experiment, 24 animals were purchased and randomly divided into four groups according to different conditions: (a) control group (N = 6), animals received an i.v. infusion of saline without LPS (LPS-sham); (b) LPS group (N = 6), animals received an i.v. infusion of saline with LPS as indicated above. When experimental ARDS was diagnosed in LPS group (PaO2/FiO2 is equal or less than 200 mmHg with a PEEP equal to 5 cmH2O), animals in control and LPS group were all killed for bronchoalveolar lavage fluid (BALF) and histologic assessment in order to aid further diagnosis of lung injury. (c) LPS plus HA-sham group (N = 6), animals received an i.v. infusion of saline with LPS. Immediately after ARDS was well established, HA-sham treatment was started by using a hollow fiber membrane hemofilter (Fresenius) with the ultrafiltration line clamped. Two animals in this group were excluded because they died or developed severe sepsis/septic shock and refractory acidosis despite active liquid recovery and vasopressor administration before moderate ARDS diagnosis; (d) LPS plus HA group (N = 6), animals received an i.v. infusion of saline with LPS, and real HA treatment was started by using a disposable hemoperfusion cartridge (HA330 resin, styrene divinylbenzene copolymers, with a blood flow of 200–250 ml/min, volume of 185 ml; Jafron Biomedical Co., Ltd., Zhuhai, GuangDong, China; http://www.jafron.com/). Two pigs were also discarded because they died of septic shock and severe disturbance of water, electrolyte and acid base before the establishment of hemoperfusion circulation. HA-sham and HA treatment lasted for 3 h, and thereafter, the animals were monitored for an extended observation period of 5 h and then killed with a bolus injection of 10 ml of 15% KCl. BAL fluid collection and lung tissue harvesting were performed immediately upon exsanguination and sternotomy performance for the measurements of inflammatory markers, proteomes and for histologic evaluation. Parameters of hemodynamics, blood gases and lung mechanics were recorded every hour following the start of LPS or sham LPS infusion until the end of experiment. Plasma samples were also prepared in the corresponding time points. During the experiment, all pigs were continuously infused with Ringer lactate solution or saline at a rate of 12 ml/kg/h at the start of the experiment. The infusion rate was increased to 15–20 ml/kg/h if the MAP was less than 70–50 mmHg. However, if pulmonary artery wedge pressure (PAWP) continuously raised and exceeded 12 mmHg, the rate of infusion should be reduced to prevent fluid overload. Meanwhile, norepinephrine (0.5–1.5 μg/kg/min) was then used to achieve this level of mPAP in LPS-treated pigs. Body temperature was maintained over 36 °C by using a heating blanket. The experimental protocol was summarized in Additional file 2: Fig. S1.

Assessment of the LPS-induced ARDS porcine model

To determine whether ARDS has occurred, at least four main features of ARDS should be assessed: (1) abnormalities of gas exchange. A ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO2/FiO2) ≤ 200 mmHg at PEEP = 5 cmH2O (clinical diagnostic criteria of moderate ARDS) is the initial evaluating criteria;(2)a remarkable leakage of alveolar barrier as indicated by the significant increase of lung wet-to-dry weight ratio, EWLW and PVPI; (3) a significant infiltration of inflammatory cells and production of inflammatory cytokines in both circulation and lung tissues (plasma and lung IL-6, IL-8, IL-1β, IL-17A and TNF-α levels were measured in our study); (4) diffuse alveolar damage (DAD) as determined by lung histopathological examination [14].

HA330 cartridge-directed hemoadsorption

The HA330 is an electrically neutral microporous resin that is a powerful new weapon in the clearance of “cytokine storm” occurred in sepsis [10]. Detailed information is shown in Additional file 1: Supplement-Methods.

BALF recovery

Sixty milliliter ice-cold saline was used to collect BALF in the left upper, middle and lower lobes. Detailed information is shown in Additional file 1: Supplement-Methods.

Assessment of total protein contents in BALF

BCA (bicinchoninic acid) protein assay reagent kit (Pierce Biotechnology, Rockford, IL, USA) was used. Detailed information is shown in Additional file 1: Supplement-Methods.

Lung tissue collection and histopathological evaluation

The right lower lobe was excised, fixed and sliced for routine hematoxylin and eosin (H&E) staining. ALI scoring was done according to a consensus report published previously [14] (Additional file 3: Table S1). Detailed information is shown in Additional file 1: Supplement-Methods.

Lung water assessed by gravimetric method

Samples from unused right lung lobes were dissected free of non-lung parenchymal tissue, placed in a dish and weighed (wet weight). Then, they were dried in an oven at 80 °C and weighed daily until their weight was maintained unchanged (dry weight). The total water content of the lung was crudely estimated as a wet-to-dry weight ratio (W/D).

Concentrations of proinflammatory mediators in circulation and lung tissues

IL-1β, IL-6, IL-8, TNF-α and IL-17A were measured by ELISA kits (Bluegene Biotech CO., LTD, Shanghai, China). Detailed information is shown in Additional file 1: Supplement-Methods.

Plasma and lung proteome

Protein samples of plasma, BALF and lung tissue in HA or HA-sham treatment group were collected and received iTRAQ-labeled (Applied Biosystems, Foster City, CA, USA) mass spectrometric analysis. Bioinformatics analysis was also performed [15, 16]. Detailed information is shown in Additional file 1: Supplement-Methods.

Statistical analysis

The data are shown as the mean ± SEM. Parametric data between multiple groups were compared by using the Kruskal–Wallis test and followed by Mann–Whitney U test if statistically significant. Mann–Whitney U test was also used for the comparison between two independent continuous variables. Data were analyzed using the SPSS statistical software package for Windows, version 13.0 (SPSS, Chicago, IL, USA), and P < 0.05 was considered as statistically significant.

Results

Intravenous infusion of endotoxin causes sharp changes in physiological parameters

The ratio of PaO2/FiO2 and alveolar-arterial oxygen partial pressure difference (AaDO2) in pigs that received LPS infusion declined gradually (from 440 ± 19 to 157 ± 23 mmHg, P < 0.001, Fig. 1a; Table 1). After LPS infusion, CO was firstly increased and then decreased when moderate ARDS was diagnosed. However, the changes did not reach statistical difference when compared with saline group. LPS infusion increased MPAP (18.8 ± 1.5 vs. 41.0 ± 1.7 mmHg, P < 0.001, Fig. 1b; Table 2) and PVRI (201 ± 13 vs. 781 ± 74 dyn s/cm5/m2, P < 0.001, Table 2). However, MAP and SVRI continued to decrease (Table 2). In addition, pulmonary mechanics were also damaged as shown by an increase in PAWPeak, PAWPlateau and resistance and a decrease in pulmonary static compliance (Fig. 1c, d; Table 1).
Figure 1
Fig. 1

LPS impairs lung function and alveolar-capillary barriers. Pigs were allocated into intravenous saline and LPS group, respectively. Parameters of oxygenation, hemodynamics and lung mechanics were recorded at different time points from baseline to the end of the experiment (T0). BALF and lung tissues were collected at T0. PaO2/FiO2 (a) was measured by using blood samples from femoral artery on a blood gas analysis instrument. The value of mPAP (b) was gained by Swan-Ganz catheter implantation into jugular vein. Compliance (c) and resistance (d) were recorded by using Drager Evita 4 ventilator. EVLWI (e) and PVPI (f) were measured by PiCCO system at baseline and a series of time points until ALI was well established (T0). g Whole protein content in the BALF of pigs was detected by using BCA protein assay kit. h The ratio of wet/dry lung weight of saline control and LPS challenge pigs. i Whole-cell counts in the BALF collected from both groups of pigs. j and k were the representative histology sections of controls and LPS challenge pigs. HE sections are from one representative animal per group. l Lung injury scores were calculated according to ATS report which was in detail described in the “Methods.” Data points are expressed as mean ± SEM, N = 6 of each group. Statistical significance between saline and LPS group per point of measurement is shown as *P < 0.05; **P < 0.01; ***P < 0.001, respectively

Table 1

Variables determining oxygenation and lung mechanics in saline controls and LPS-challenged animals

Parameter

Group

Time (h)

Baseline

−3 h

−2 h

−1 h

T0

PaO2/FiO2 (mmHg)

NS

466 ± 26

458 ± 60

531 ± 51

509 ± 60

479 ± 34

LPS

440 ± 19

312 ± 51

242 ± 36***

194 ± 10***

157 ± 23***

PaCO2 (mmHg)

NS

35.2 ± 2.8

30.8 ± 2.8

30.5 ± 1.8

32.3 ± 1.1

31.8 ± 1.49

LPS

36.8 ± 2.4

30.2 ± 1.8

37.5 ± 1.5

36.5 ± 3.0

44.7 ± 5.0**

AaDO2 (mmHg)

NS

47 ± 7

48 ± 14

52 ± 1

51 ± 12

60 ± 4

LPS

63 ± 5

124 ± 20

143 ± 15**

213 ± 53**

224 ± 48**

PAWPeak (mbar)

NS

16.5 ± 1.8

16.5 ± 1.5

16.5 ± 1.7

17.3 ± 2.0

17.3 ± 1.8

LPS

21.3 ± 0.9

27.2 ± 1.8**

30.2 ± 2.4***

31.2 ± 2.4***

35.7 ± 2.5***

PAWPlateau (mbar)

NS

12.2 ± 1.8

11.5 ± 1.7

12.2 ± 2.0

13.2 ± 2.3

13.8 ± 2.2

LPS

15.3 ± 1.2

18.8 ± 1.4

22.3 ± 2.3**

25.7 ± 2.5***

27.3 ± 3.2***

Resistance (mbar/l/s)

NS

9.3 ± 1.4

7.9 ± 1.2

8.1 ± 1.3

7.5 ± 1.1

8.1 ± 1.3

LPS

8.5 ± 0.4

13.6 ± 2.5

15.7 ± 3.5

15.1 ± 3.2

14.7 ± 2.2

Compliance (ml/mbar)

NS

31.2 ± 3.5

33.3 ± 3.0

34.5 ± 4.0

35.6 ± 4.3

32.8 ± 3.3

LPS

28.2 ± 2.7

23.0 ± 2.1

21.4 ± 2.3*

20.7 ± 2.9**

16.7 ± 1.8**

Oxygenation and ventilation parameters in saline control and LPS challenge animals at baseline and a series of time points until the end of the experiment when ALI model was diagnosed (data shown are mean ± SEM, N = 6 of each group; *P < 0.05; **P < 0.01; ***P < 0.001 versus control group). PaO2, oxygen partial pressure; FiO2, inspiratory oxygen fraction; PaCO2, carbon dioxide partial pressure; PAWPeak, peak airway pressure; PAWPlateau, plateau airway pressure

Table 2

Systemic and pulmonary hemodynamic measurements in saline controls and LPS-challenged animals

Parameter

Group

Time (h)

Baseline

−3 h

−2 h

−1 h

T0

CO (l/min)

NS

4.1 ± 0.3

4.5 ± 0.4

4.1 ± 0.4

4.2 ± 0.4

4.2 ± 0.4

LPS

4.1 ± 0.3

4.1 ± 0.5

5.1 ± 0.3

5.0 ± 0.3

3.4 ± 0.3

MAP (mmHg)

NS

105 ± 6

98 ± 6

102 ± 8

101 ± 7

102 ± 8

LPS

113 ± 3

78 ± 8

56 ± 4***

57 ± 5***

54 ± 5***

SVRI (dyn s/cm5/m2)

NS

1783 ± 198

1810 ± 169

1927 ± 148

1822 ± 183

1909 ± 218

LPS

2399 ± 238

1987 ± 217

1002 ± 111**

952 ± 56**

1160 ± 97*

mPAP (mmHg)

NS

16.5 ± 1.0

16.7 ± 0.5

15.7 ± 1.2

17.8 ± 1.5

18.5 ± 1.2

LPS

18.8 ± 1.5

28.8 ± 1.9***

3.3 ± 2.0***

34.7 ± 2.7***

41.0 ± 1.7***

PVRI (dyn s/cm5/m2)

NS

204 ± 20

193 ± 16

231 ± 48

209 ± 35

201 ± 13

LPS

364 ± 40

552 ± 115***

542 ± 67**

634 ± 120***

781 ± 74***

PAWP (mmHg)

NS

6.0 ± 1.2

6.5 ± 1.5

6.3 ± 1.4

6.8 ± 1.5

6.8 ± 1.2

LPS

4.0 ± 1.2

5.5 ± 0.6

8.0 ± 0.6

9.0 ± 0.9

12.2 ± 1.4*

EVLWI (ml/kg)

NS

9.0 ± 0.5

9.7 ± 0.9

9.3 ± 0.5

9.5 ± 0.6

10.0 ± 0.9

LPS

8.0 ± 0.5

9.7 ± 0.7

9.8 ± 0.9

11.0 ± 0.8

15.4 ± 1.3***

PVPI

NS

2.7 ± 0.1

2.8 ± 0.3

3.0 ± 0.3

3.0 ± 0.3

2.9 ± 0.2

LPS

2.7 ± 0.2

3.6 ± 0.3

4.0 ± 0.7

4.6 ± 0.7

5.6 ± 0.5***

Hemodynamic parameters are compared between the saline control and LPS-challenged group. (Data are mean ± SEM, N = 6 of each group; *P < 0.05, **P < 0.01, ***P < 0.001; versus control group)

CO cardiac output, MAP mean arterial pressure, SVRI systemic vascular resistance index, MPAP mean pulmonary arterial pressure, PVRI pulmonary vascular resistance index, PAWP pulmonary artery wedge pressure, EVLWI extravascular lung water index, PVPI pulmonary vascular permeability index

Intravenous infusion of endotoxin causes high-permeability pulmonary edema and lung histologic damages

The EVLWI continuously increased after LPS infusion until ARDS was diagnosed (from 8.0 ± 0.5 ml/kg in baseline to 15.4 ± 1.3 ml/kg at the end of this experiment when ARDS was established, P < 0.001; Fig. 1e). In parallel, there was also a remarkable increase in lung wet/dry ratio in LPS-challenged pigs compared with saline group (Fig. 1h). The alveolar-capillary membrane was also seriously injured by LPS infusion as manifested by a significant increase in both pulmonary vascular permeability index (PVPI) and whole BAL protein concentration (Fig. 1f, g). Infusion of LPS in the endotoxin challenge group was also associated with an increase in the numbers of whole BAL cell counting (Fig. 1i). To determine the histopathological features of ALI model, subset of animals (N = 6 in LPS and saline group, respectively) were killed when ARDS model was diagnosed based on oxygenation parameter (PaO2/FiO2 ≤ 200 mmHg at PEEP = 5 cmH2O). Histologic examinations from animals receiving LPS demonstrated alveolar bleeding, microatelectasis, perivascular edema, marked leukocyte sequestration in alveolar septa and lumen, thickened alveolar walls, and the presence of proteinaceous debris in the alveolar space as compared to control subjects (Fig. 1j–l, Additional file 4: Fig. S2).

Intravenous infusion of endotoxin augments the expressions of systemic and pulmonary inflammatory cytokines

As shown by ELSA assay in Fig. 2, there was no difference in the baseline concentration of plasma IL-1β (Fig. 2a), IL-6 (Fig. 2d), IL-8 (Fig. 2g), TNF-α (Fig. 2j) and IL-17A (Fig. 2m) between LPS and saline groups, but all of these cytokines increased rapidly when challenged with LPS infusion at T0 compared with saline infusion. We also determined the levels of these inflammatory cytokines within BALF and lung homogenates to assess the inflammatory response in the alveolar compartment. ELISA assay showed significant increased levels of these cytokines in BALF and lung homogenates after LPS challenge except IL-17A, which was remarkable increased in BALF but remained unchanged in lung homogenates at T0 (Fig. 2).
Figure 2
Fig. 2

Concentrations of circulating and pulmonary inflammatory parameters. In LPS group, plasma samples were collected before LPS challenge (baseline) and at the time when ARDS model had been well established (T0). BALF and lung homogenates were also prepared at necropsy. Samples from saline control group were also obtained at the corresponding time points. The level of circulating and pulmonary IL-1β (a–c), IL-6 (d–f), IL-8 (g–i), TNF-α (j–l) and IL-17A (m–o) was detected by using commercial ELISA kits. Data are presented as mean ± SEM (N = 6 of each group). Compared with saline (NS) group, *P < 0.05; **P < 0.01; ***P < 0.001

Hemoadsorption improves oxygenation and lung mechanics in pigs challenged with endotoxin

We found that treatment with HA increased LPS-impaired oxygenation (387 ± 10 mmHg at baseline vs. 183 ± 6 mmHg at T0 vs 315 ± 22 mmHg at 8 h after HA; Fig. 3a; Table 3). In contrast, in endotoxin-challenged pigs that did not receive HA (HA-sham) treatment, the ratio of PaO2/FiO2 was only slightly increased at 8 h after HA-sham (Fig. 3a; Table 3). Treatment with HA significantly or showed a trend toward decreasing PAWPeak, PAWPlateau, lung resistance and the impairment of static compliance induced by endotoxin infusion when all pigs data were pooled together and compared with HA-sham group (Fig. 3c, d; Table 3). However, HA did not alter the impairment of systemic/pulmonary hemodynamic parameters (Fig. 3b; Table 4).
Figure 3
Fig. 3

Effects of HA on oxygenation, lung mechanics and alveolar-capillary barriers. Pigs were challenged with LPS (50 μg/kg) intravenously to recapitulate the features of ARDS. When ARDS was well established (T0), animals received hemoadsorption (HA) or sham-hemoadsorption treatment for 3 h. Following another 5-h observation, animals were killed for BALF and lung tissue processing. At baseline, T0, and a series of time points during (2 h) and after HA (or HA-sham) treatment (4, 6 and 8 h), parameters of oxygenation and lung mechanics were recorded. PaO2/FiO2 (a) was measured by using blood samples from femoral artery on a blood gas analysis instrument. The value of mPAP (b) was gained by Swan-Ganz catheter implantation into jugular vein. Resistance (c) and compliance (d) were recorded by using Drager Evita 4 ventilator. EVLWI (e) and PVPI (f) were measured by PiCCO system at indicated time points (baseline, T0, 2, 4, 6 and 8 h following HA or HA-sham treatment). BALF protein (g) was assessed at 8 h after HA (or HA-sham) as described in “Methods”. h The ratio of wet/dry lung weight of animals in both groups was calculated by gravimetric method. i Whole-cell counts in the BALF collected from both groups of pigs were numerated by using a counting plate. j and k were the representative lung histology sections of pigs in LPS + HA (sham) and LPS + HA groups. HE sections are from one representative animal per group. l Lung injury scores were calculated according to ATS report which was in detail described in the “Methods.” Data points represent as mean ± SEM, N = 3–4 of each group and time point. Statistical significance between HA and HA-sham group per point of measurement is shown as *P < 0.05

Table 3

Variables determining oxygenation and lung mechanics in LPS + HA (sham)- and LPS + HA-treated animals

Parameter

Group

Time (h)

Baseline

T0

2 h

4 h

6 h

8 h

PaO2/FiO2 (mmHg)

LPS + HA (sham)

329 ± 55

164 ± 10†

131 ± 20†

129 ± 21†

178 ± 68

169 ± 53

LPS + HA

387 ± 10

183 ± 6†

254 ± 44*

211 ± 31†

264 ± 31

315 ± 22*§

PaCO2 (mmHg)

LPS + HA (sham)

45 ± 4

40 ± 7

45 ± 17

46 ± 14

46 ± 16

42 ± 14

LPS + HA

37 ± 5

53 ± 6†

59 ± 9†

54 ± 3†

51 ± 2

45 ± 3

AaDO2 (mmHg)

LPS + HA (sham)

96 ± 24

170 ± 6

363 ± 129

330 ± 103

371 ± 102†

358 ± 96

LPS + HA

79 ± 10

172 ± 29†

368 ± 68†

368 ± 77†

334 ± 81†

296 ± 66†

PAWPeak (mbar)

LPS + HA (sham)

17.7 ± 1.8

32.0 ± 2.6†

29.7 ± 5.2†

29.7 ± 2.7†

28.3 ± 1.7†

26.7 ± 3.2

LPS + HA

18.9 ± 1.5

29.0 ± 1.0†

26.3 ± 1.9†

26.3 ± 1.8†

24.7 ± 1.8

24.3 ± 2.3

PAWPlateau (mbar)

LPS + HA (sham)

13.3 ± 0.9

21.0 ± 1.0†

22.7 ± 2.9†

23.3 ± 2.4†

21.0 ± 1.0†

21.7 ± 0.9†

LPS + HA

15.3 ± 1.8

24.7 ± 1.3†

22.0 ± 1.2†

21.0 ± 1.0†§

20.3 ± 0.9†§

19.0 ± 0.0*†§

Resistance (mbar/l/s)

LPS + HA (sham)

8.0 ± 1.1

15.0 ± 1.8

17.5 ± 4.6

13.4 ± 3.9

13.7 ± 3.6

13.3 ± 4.0

LPS + HA

8.2 ± 1.0

11.7 ± 1.8

8.8 ± 1.5

8.7 ± 1.2

8.0 ± 1.1

7.2 ± 1.2§

Compliance (ml/mbar)

LPS + HA (sham)

32.6 ± 2.9

20.1 ± 6.1

19.6 ± 7.7

20.2 ± 6.0

20.6 ± 5.0

21.1 ± 5.9

LPS + HA

27.1 ± 2.9

19 ± 2.2†

20.1 ± 1.1

22.5 ± 2.0

22.7 ± 2.8

23.3 ± 2.3

Oxygenation and ventilation parameters in LPS + HA (sham)- and LPS + HA-treated animals at baseline and a series of time points until the end of the experiment (data are mean ± SEM, N = 3–4 of each group; *P < 0.05 when compared between groups; † P < 0.05 when compared with baseline within per group; § P < 0.05 versus T0 within per group). PaO2, oxygen partial pressure; FiO2, inspiratory oxygen fraction; PaCO2, carbon dioxide partial pressure; PAWPeak, peak airway pressure; PAWPlateau, plateau airway pressure

Table 4

Systemic and pulmonary hemodynamic measurements compared between LPS + HA (sham) and LPS + HA groups

Parameter

Group

Time (h)

Baseline

T0

2 h

4 h

6 h

8 h

CO (l/min)

LPS + HA (sham)

6.36 ± 0.41

5.50 ± 1.98

4.86 ± 1.28

5.35 ± 1.13

5.17 ± 1.10

5.56 ± 1.27

LPS + HA

4.98 ± 0.48

4.99 ± 0.78

5.34 ± 0.94

6.08 ± 0.97

5.05 ± 0.89

5.15 ± 0.40

MAP (mmHg)

LPS + HA (sham)

125 ± 6

82 ± 3

92 ± 20

106 ± 21

104 ± 25

96 ± 24

LPS + HA

118 ± 7

85 ± 15

74 ± 9

86 ± 12

82 ± 17

80 ± 16

SVRI (dyn s/cm5/m2)

LPS + HA (sham)

1699 ± 59

1120 ± 154

1813 ± 688

1788 ± 468

1681 ± 354

1454 ± 248

LPS + HA

1992 ± 156

1465 ± 423

1143 ± 231

1210 ± 347

1576 ± 778

1291 ± 461

mPAP (mmHg)

LPS + HA (sham)

23.0 ± 2.6

36.3 ± 5.6

41.3 ± 3.2

38.3 ± 5.8

38.3 ± 5.4

34.0 ± 5.1

LPS + HA

22.7 ± 0.3

37.7 ± 5.2

44.3 ± 5.2

39.3 ± 8.0

35.3 ± 7.8

31.3 ± 10

PVRI (dyn s/cm5/m2)

LPS + HA (sham)

229 ± 31

477 ± 202

518 ± 181

467 ± 85

441 ± 92

343 ± 25

LPS + HA

248 ± 19

404 ± 60

499 ± 72

421 ± 156

483 ± 196

416 ± 145

PAWP (mmHg)

LPS + HA (sham)

9.7 ± 2.3

12.7 ± 3.2

14.7 ± 3.0

12.0 ± 3.1

14.0 ± 4.2

13.0 ± 2.6

LPS + HA

8.3 ± 1.2

11.0 ± 1.2

16.3 ± 1.8

13.0 ± 1.7

11.0 ± 2.0

11.7 ± 3.0

EVLWI (ml/kg)

LPS + HA (sham)

10.1 ± 3.5

13.1 ± 1.4

13.0 ± 0.6

15.9 ± 2.5

13.7 ± 1.0

12.9 ± 2.0

LPS + HA

8.1 ± 0.3

12.4 ± 1.8

12.5 ± 1.5

13.7 ± 1.5

13.0 ± 2.1

10.1 ± 2.3

PVPI

LPS + HA (sham)

3.2 ± 1.0

4.2 ± 0.2

3.7 ± 0.5

4.4 ± 0.5

4.1 ± 0.2

4.0 ± 0.3

LPS + HA

2.5 ± 0.2

4.1 ± 0.5

3.9 ± 1.0

3.6 ± 0.3

3.1 ± 0.7

2.9 ± 0.9

Hemodynamic parameters are shown in the LPS + HA (sham) and LPS + HA groups. Data are mean ± SEM, N = 3–4 of each group; CO, cardiac output; MAP, mean arterial pressure; SVRI, systemic vascular resistance index; MPAP, mean pulmonary arterial pressure; PVRI, pulmonary vascular resistance index; PAWP, pulmonary artery wedge pressure; EVLWI, extravascular lung water index; PVPI, pulmonary vascular permeability index

Hemoadsorption blunts lung edema and histopathological signs of ARDS

Compared with LPS + HA-sham group, HA therapy for ARDS pigs caused a decrease in EVLWI, PVPI, lung wet-to-dry weight ratio and BALF cell count (Fig. 3e, f, h, i; Table 4). However, the changes did not reach statistical difference when compared with LPS + HA-sham group. But HA therapy can significantly reduce total BALF protein as compared to HA-sham treatment (Fig. 3g). These beneficial alterations were further reflected by reduced histologic signs of inflammation and injury (Fig. 3j–l).

Hemoadsorption reduces circulating and alveolar cytokine levels

ELISA assay showed that plasma level of IL-1β and IL-6 induced by endotoxin was significantly blunted by HA treatment compared with HA-sham treatment (Fig. 4a, d). HA also elicited a remarkable decrease in the expression of IL-1β and IL-6 in both BALF and lung homogenate (Fig. 4b, c, e, f). Plasma and lung homogenate levels of IL-8 were also decreased (Fig. 4g, i). BALF levels of TNF-α and IL-17A were significantly reduced by HA treatment (Fig. 4k, n).
Figure 4
Fig. 4

Effect of HA on the production of LPS-induced circulating and pulmonary inflammatory cytokines. Pigs were allocated into LPS + HA (sham) and LPS + HA groups. Plasma was collected at baseline, and at the time point when ALI model was diagnosed (T0) and the end of the experiment schedule (8 h after T0). BALF and lung homogenates were prepared after pigs were euthanized. The systemic and pulmonary cytokine levels of IL-1β (a–c), IL-6 (d–f), IL-8 (g–i), TNF-α (j–l) and IL-17A (m–o) were detected by using ELISA kits. Values are mean ± SEM, N = 4 of each group. *P < 0.05; **P < 0.01; ***P < 0.001 when compared between LPS + HA (sham) and LPS + HA groups; † P < 0.05 versus baseline and § P < 0.05 versus T0 when compared within each group

Hemoadsorption-altered plasma and pulmonary proteome

First, plasma proteome was analyzed. The differentially accumulated proteins (T0 vs baseline) and their dynamic changes after HA/HA-sham treatment (8 h after T0 vs. baseline) are shown in Additional file 5: Fig. S3. These proteins were classified into several categories based on biological process analysis (Tables 5, 6). We identified four plasma proteins , i.e., interleukin-1 receptor antagonist protein (IL-1Ra), inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4), matrix metallopeptidase (MMP)-1 and MMP-10, that were up-regulated at T0 in these two groups, but sharply reduced after HA treatment while further increased in HA-sham group (Fig. 5a, b). Differentially expressed proteins (these proteins were comparable at T0 when compared with HA with HA-sham group) after 8-h HA or HA-sham treatment, and their GO annotations are also shown in Additional file 6: Table S2 and Additional file 7: Fig. S4. We then analyzed proteome in BALF and lung homogenate samples. Differentially expressed proteins compared between HA and HA-sham groups are shown in Additional file 8: Table S3, Additional file 9: Table S4, Additional file 10: Table S5, Additional file 11: Table S6. The most five relevant GO categories (P value less than 0.05) are shown in Fig. 5c, d. KEGG pathway analysis showed that these differentially expressed proteins were involved in the canonical signaling pathways (Fig. 5e, f).
Table 5

Ontology groups and associated differentially expressed plasma proteins in the time points of T0 and 8 h after HA-sham treatment versus baseline

GO biological process

Accession

Protein name

Fold change over baselinea

T0/baseline

8 h/baseline

Acute-phase response/acute inflammatory response

P79263

Inter-alpha-trypsin inhibitor heavy chain H4

1.22

2.17

F1SH92

Inter-alpha-trypsin inhibitor heavy chain H4

1.39

2.04

Q29056

Interleukin-1 receptor antagonist protein

1.49

1.51

F1SFI7

Alpha-2-HS-glycoprotein (Fragment)

0.76

0.49

Q29014

Alpha-1 acid glycoprotein (Fragment)

0.68

0.49

Q8SPS7

Haptoglobin

0.74

0.57

Q6S4N2

Heat shock 70 kDa protein 1B

0.64

0.65

Regulation of immune system process

P01025

Complement C3

1.45

0.88

A5PF00

B-factor, properdin

0.75

0.62

F1RMN7

Hemopexin

0.70

0.63

Q69DL4

Complement C1qB (Fragment)

0.81

0.60

A0SEH0

Complement component C6

0.71

0.76

Q29041

Ficolin-2

0.75

0.69

Defense response/response to stress

P52552

Peroxiredoxin-2 (Fragment)

1.28

1.30

P32195

Protegrin-2

4.76

2.43

O02705

Heat shock protein HSP 90-alpha

1.37

2.56

Q6QR67

Resistin

5.00

3.06

Proteolysis

C9VZX4

Matrix metallopeptidase 1

1.79

3.98

C9VZX5

Matrix metallopeptidase 10

1.13

1.53

F2Z528

Proteasome subunit alpha type

1.22

1.22

F2Z5K2

Proteasome subunit alpha type

1.28

1.21

I3LQ51

Proteasome subunit beta type

1.49

1.50

P03974

Transitional endoplasmic reticulum ATPase

1.35

2.27

Q9GMA6

Alpha-1-antichymotrypsin 2

0.81

0.55

C4PGL9

Mannan-binding lectin serine peptidase 2

0.79

0.97

F1SCF0

Alpha-1-antitrypsin

0.81

0.66

Coagulation

F1RPW2

Coagulation factor V

0.66

0.45

F1RZ36

Coagulation factor VIII

0.64

0.74

O97507

Coagulation factor XII

0.76

0.66

K7GQL2

Coagulation factor XIII, A1 polypeptide

0.71

0.79

F1RX36

Fibrinogen alpha chain

0.83

1.11

P14460

Fibrinogen alpha chain (Fragment)

1.47

3.12

P14477

Fibrinogen beta chain (fragment)

1.39

2.30

P06867

Plasminogen

0.77

0.57

F1SB81

Plasminogen

0.59

0.59

B3STX9

Prothrombin

0.68

0.76

Negative regulation of blood coagulation

I3LRJ4

Vitamin K-dependent protein C

0.69

0.57

Metabolic process

Q29214

60S acidic ribosomal protein P0

1.47

2.45

F1RYZ0

60S acidic ribosomal protein P2

2.17

4.72

P01965

Hemoglobin subunit alpha

1.39

0.68

F1RII7

Hemoglobin subunit beta

1.28

0.74

A0SNU7

Glyceraldehyde-3-phosphate dehydrogenase (fragment)

1.23

1.41

G9F6X8

Prolyl 4-hydroxylase beta polypeptide

1.45

2.14

F1SN27

Sorbitol dehydrogenase

1.67

3.13

Regulation of lipid storage

Q2LE37

Apolipoprotein M

1.25

1.02

Q29248

Apolipoprotein A-I (Fragment)

0.79

0.79

Cellular metal ion homeostasis

Q8WMN8

Lactoferrin (Fragment)

1.64

0.93

P09571

Serotransferrin

0.77

0.63

Transport

P04404

Chromogranin-A (Fragment)

1.75

1.89

Q29545

Inhibitor of carbonic anhydrase

0.67

0.54

A4US67

Paraoxonase

0.75

0.67

F1RUN2

Serum albumin

0.76

0.60

P50390

Transthyretin

0.81

0.76

Positive regulation of cell differentiation

Q0PM28

Pigment epithelium-derived factor

0.70

0.84

Multicellular organismal process

P00761

Trypsin

0.78

0.55

Response to unfolded protein

F1RS36

78 kDa glucose-regulated protein

1.33

1.38

Cytoskeleton organization

I3LVD5

Actin, cytoplasmic 1

1.64

1.09

A0A0B8RSX6

Filamin A, alpha

1.45

1.71

B6VNT8

Cardiac muscle alpha actin 1

1.82

1.39

Q6QA25

Tropomyosin 3

1.59

1.91

P67937

Tropomyosin alpha-4 chain

1.23

1.29

Q767L7

Tubulin beta chain

1.37

0.84

P02543

Vimentin

1.54

5.13

Obsolete GTP catabolic process

Q0PY11

Elongation factor 1-alpha

1.35

1.37

Chromosome organization

P62802

Histone H4

2.50

1.87

Tissue remodeling

Q711S8

Secreted phosphoprotein 24

0.82

0.79

Regulation of biological process

F1S682

Sulfhydryl oxidase

0.80

0.86

aNote that changes are expressed as relative abundance of the plasma proteins at T0 or 8 h after HA-sham treatment compared with baseline within the LPS + HA (sham) group. A fold change ≥ 1.20, p < 0.05 represents more protein abundance in T0 or 8 h versus baseline. By contrast, a fold change ≤ 0.83, p < 0.05 represents less protein abundance in T0 or 8 h versus baseline

Table 6

Ontology groups and associated differentially expressed plasma proteins in the time points of T0 and 8 h after HA treatment versus baseline

GO biological process

Accession

Protein name

Fold change over baselinea

T0/baseline

8 h/baseline

Acute-phase response/acute inflammatory response

Q29014

Alpha-1 acid glycoprotein (Fragment)

2.70

0.87

K9J6H8

Alpha-2-macroglobulin

1.82

1.01

I3L6K3

C-reactive protein

1.43

2.50

F1RJ76

C-reactive protein

1.27

1.32

Q8SPS7

Haptoglobin

2.08

1.00

P79263

Inter-alpha-trypsin inhibitor heavy chain H4

1.89

1.78

F1SH92

Inter-alpha-trypsin inhibitor heavy chain H4

1.47

1.19

Q29056

Interleukin-1 receptor antagonist protein

2.44

1.44

F1S9B8

Serum amyloid A protein

1.64

1.35

Regulation of immune system process

P01025

Complement C3

1.50

1.34

F1SMJ1

Complement component C7 (Fragment)

1.23

1.07

A5PF00

B-factor, properdin

2.50

0.95

F1RMN7

Hemopexin

1.85

1.08

L8B0S2

IgG heavy chain

1.82

1.00

L8B0W9

IgG heavy chain

1.30

0.94

K7ZPU8

IgG heavy chain constant region (Fragment)

1.59

0.72

Q4Z8N7

Plasma platelet-activating factor acetylhydrolase

1.20

1.38

P28491

Calreticulin

0.81

1.29

B0LUW3

Chemerin

0.62

0.79

F1STZ4

Complement C1q subcomponent subunit A

0.83

0.82

Q29041

Ficolin-2

0.77

0.72

A5A758

Keratin 1 (Fragment)

0.53

0.69

C4PGL9

Mannan-binding lectin serine peptidase 2

0.65

0.75

Defense response/response to stress

A2SW51

Monocyte differentiation antigen CD14

1.64

1.60

P52552

Peroxiredoxin-2 (Fragment)

1.59

1.64

P32195

Protegrin-2

1.25

1.05

B3STX9

Prothrombin

1.28

1.01

F5XVC2

von Willebrand factor

1.35

1.07

Q6QR67

Resistin

1.79

1.52

Proteolysis

Q9GMA6

Alpha-1-antichymotrypsin 2

1.47

1.03

F1SCF0

Alpha-1-antitrypsin

2.04

0.87

C9VZX4

Matrix metallopeptidase 1

1.47

1.22

C9VZX5

Matrix metallopeptidase 10

1.43

1.21

Coagulation

P14460

Fibrinogen alpha chain (Fragment)

1.54

3.30

P14477

Fibrinogen beta chain (Fragment)

1.43

1.78

F1RQ75

Coagulation factor IX

0.78

0.60

F1RPW2

Coagulation factor V

0.79

0.67

Q19AZ7

Coagulation factor VII isoform b protein

0.72

0.81

K7GQL2

Coagulation factor XIII, A1 polypeptide

0.51

0.54

Negative regulation of blood coagulation

I3LRJ4

Vitamin K-dependent protein C

0.74

0.64

Metabolic process

F1S1G8

Amine oxidase

1.64

1.01

P01965

Hemoglobin subunit alpha

2.17

1.11

F1RII7

Hemoglobin subunit beta

1.89

1.22

Q29052

Inter-alpha-trypsin inhibitor heavy chain H1

1.32

1.08

F8SIP2

EGF-containing fibulin-like extracellular matrix protein 1

0.80

1.09

O02668

Inter-alpha-trypsin inhibitor heavy chain H2

0.74

0.64

I3LL80

L-lactate dehydrogenase

0.81

0.65

Q29126

Protein WAP-3

0.31

0.84

Regulation of lipid storage

A0A0F6TNY5

APOB O

1.43

1.09

Q29433

Apolipoprotein B (Fragment)

2.17

1.21

Q2LE37

Apolipoprotein M

1.23

1.04

O97674

Lipoprotein lipase (Fragment)

0.62

0.64

D3Y264

Apolipoprotein C-II

0.80

0.63

F1RM45

Apolipoprotein E

0.75

0.89

Q03472

Apolipoprotein R

0.72

0.60

Q8WMN7

Plasma phospholipid transfer protein

0.79

0.85

Cellular metal ion homeostasis

I3VKE6

Ceruloplasmin

1.30

1.07

Q6YT39

Lactotransferrin

1.61

1.33

P09571

Serotransferrin

2.33

0.91

D7RK08

Transferrin receptor protein

1.45

1.30

Transport

F1RUN2

Serum albumin

2.08

1.01

P50390

Transthyretin

1.33

0.89

Positive regulation of cell differentiation

Q0PM28

Pigment epithelium-derived factor

1.32

1.11

Multicellular organismal process

Q711S8

Secreted phosphoprotein 24

0.74

0.72

O11780

Transforming growth factor-beta-induced protein ig-h3

0.83

0.97

P67937

Tropomyosin alpha-4 chain

0.81

1.23

P00761

Trypsin

0.82

0.85

aNote that changes are expressed as relative abundance of the plasma proteins at T0 or 8 h after HA treatment compared with baseline within the LPS + HA group. A fold change ≥1.20, P < 0.05 represents more protein abundance in T0 or 8 h versus baseline. By contrast, a fold change ≤0.83, P < 0.05 represents less protein abundance in T0 or 8 h versus baseline

Figure 5
Fig. 5

Differentially expressed plasma, BALF and lung proteins identified with iTRAQ in LPS + HA (sham)- versus LPS + HA-treated pigs. a and b four plasma proteins that were most differentially expressed after 8-h treatment in LPS + HA (sham)- versus LPS + HA-treated pigs. Note that after LPS infusion, these proteins were up-regulated (T0/baseline); however, after HA treatment, their expression were decreased. By contrast, they were further increased after HA-sham treatment. Functional annotation for differentially expressed BALF (c) and lung homogenate (d) proteins by HA and HA-sham treatment are shown. Red bars represent the numbers of differentially expressed proteins based on three main categories: cellular component, biological process and molecular function. Enriched KEGG pathway analysis for differentially expressed BALF (e) and lung homogenate (f) proteins by HA and HA-sham treatment are shown. Red bars represent the numbers of proteins in a given pathway that differentially expressed between groups

Discussion

In this current study, we tested the efficacy of “sorbent strategy”-based HA on a porcine ARDS model and found that HA reduced circulating and alveolar levels of proinflammatory cytokines, improved oxygenation and attenuated lung injuries in the exudative phase. This provides some clue that HA330 cartridge may be a novel potential weapon fighting against the “cytokine storm” on the alveolar-capillary membrane barrier.

The most commonly used large-animal models of ARDS include endotoxin infusion, repeated lavage, oleic acid and smoke/burn injury [17]. To reproduce the most known risk factor and etiology for ARDS, which is sepsis [18], we systemically administrated endotoxin (LPS) to mimic the clinically relevant sepsis-induced ARDS. The susceptibility to LPS is highly variable and differs among different animals. Pigs, sheep, calves, and cats are more sensitive to LPS challenge. Low dosage of LPS (μg/kg range) can induce significant ARDS-like features in these animals. In contrast, animals such as rodents or dogs require much higher doses to develop lung injury (mg/kg range). This different vulnerability to LPS may be induced by the pulmonary intravascular macrophages (PIM), a lung resident population of mature macrophage [19]. 8–100 μg/kg of LPS has been used in several previous studies to develop porcine ARDS model [12, 20, 21]. In our study, low amount of LPS (50ug/kg in 500 ml saline for 2 h) can also induce the pigs to develop an abrupt decrease in oxygenation and arterial pressure and a decrease in systemic vascular resistance, needing rapid fluid resuscitation (10–20 ml/kg/h of saline) and the usage of vasopressor infusion (0.5–1.5 μg/kg/min of norepinephrine).

In most recent large-animal studies, the diagnosis of experimental ARDS is ambiguous without definite criteria [12, 18, 21, 22]. To determine whether ARDS really occurred, we adopt the four diagnostic criteria released by ATS official statement on the definition of ARDS in animals [14]. ARDS model was initially diagnosed when PaO2/FiO2 is less than 200 mmHg with a PEEP at 5 cmH2O (criteria (a) moderate ARDS in human beings according to Berlin definition). Then, the ARDS model was further assessed with other criteria listed as follows: (b) permeability. Permeability assessment was performed by using four parameters, i.e., EVLWI, PVPI, BALF protein and the ratio of wet to dry lung weight (W/D ratio). EVLW is the amount of interstitial and alveolar fluid [23]. Previous studies showed that EVLW indexed to body weight (EVLWI) is well correlated with the value obtained by gravimetry and can independently predict mortality in septic and ARDS patients [19]. We found that both EVLWI and W/D ratio were significantly increased after LPS infusion, indicating an exudative edema phase (Fig. 1; Table 2). The permeability of lung epithelium barrier can also be calculated by PVPI [24]. PVPI in this model was increased to 5.6 ± 0.5 at T0 when ARDS was diagnosed (Fig. 1; Table 2), indicating high permeable (rather than hydrostatic) pulmonary edema because it was reported that a PVPI value of 3 can distinguish these two forms of pulmonary edema [24]. Accordingly, BALF protein concentration, another leakage marker [14], was also increased after LPS infusion (Fig. 1g). (c) Histology. To our knowledge, this is the first large-animal study to assess histologic changes at the time point that ARDS was initially diagnosed by oxygenation and ahead of therapy implementation. The major histologic findings are shown in Fig. 1j–l. It is noteworthy that LPS i.v. infusion causes only modest lung edema (perivascular edema, Additional file 4: Fig. S2) as compared to ARDS patients, because the endothelium barrier is more resistant to the damage induced by LPS [19]. (d) Inflammation. We found that both circulating and alveolar inflammatory cytokines were elevated, indicating an acute “cytokine storm” was elicited in systemic and lung milieu by i.v. infusion of LPS.

Thereafter, we conducted subsequent studies to explore the “therapeutic,” rather than “prophylactic” effect of hemoadsorption (HA) on the well-established (or far-developed, rather than “immature”) ARDS model. HA was performed with the HA330 neutral microporous resin cartridge specially designed for the absorption of medium-sized inflammatory cytokines. First, we found that HA treatment increased PaO2/FiO2 gradually (Fig. 3). Several previous studies in septic patients attributed this beneficial effect to the improved hemodynamics [10, 25]. However, a previous experimental study showed that zero-balanced high-volume continuous veno-venous hemofiltration (CVVH) could improve arterial oxygenation without systemic or pulmonary hemodynamics improvement [9]. We also found that animals treated with or without HA330-based hemadsorption did not differ in their levels of MAP, SVRI, MPAP and PVRI (Table 4). Considering that HA therapy elicited a trend in reducing lung water and the permeability of alveolar-capillary membrane barrier (Fig. 3e–i), we assume that oxygenation improvement should be partly due to the reduction of alveolar fluid leakage after clearing the peak concentration of alveolar cytokines, corresponding with the “peak concentration hypothesis” for EBP modality [26]. Lung local cytokines removal may be the result of passive spillover or active transport [26]. Notably, a recent clinical study showed that the circulating and BALF levels of IL-17A were significantly increased in ARDS patients and predicted an increased influx of alveolar neutrophils, alveolar permeability and organ dysfunction [27]. Thus, reduced BALF level of IL-17A in HA treatment group may be one of the reasons for fewer lung inflammatory cells and decreased acute lung injury. Taken together, by direct/indirect removal of a variety of pathogenic proinflammatory mediators that over-expressed in plasma and lung, HA timely blunted the “cytokine storm” in the process of ARDS and restored immunologic balance at a much lower set-point. These findings were in line with a recent small clinical study on septic-induced ARDS patients [28].

In the last step, we also examined whether HA can effect the whole proteomes in plasma and lung, which has not been previously reported. We found four plasma proteins that were most differentially regulated by HA and HA-sham therapy, i.e., IL-1Ra, MMP-1, MMP-10 and ITIH4 (Fig. 5a, b). Soluble IL-1Ra, an important member in IL-1 family of cytokines [29], was dramatically elevated in ARDS and septic patients [30, 31]. A persistent elevated level of IL-1Ra indicates immunoparalysis, which greatly contributes to the later deaths who survive the initial cytokine storm in ARDS [32]. ITIH4 is a plasma glycoprotein that belongs to a serine protease inhibitor family and acts as an acute-phase protein in several diseases [33]. However, there is a lack of studies aiming to determine the role of ITIH4 as a potential diagnostic or prognostic indicator for ARDS. The matrix metalloproteinases (MMPs) are a family of proteolytic enzymes with the capacity of degrading the extracellular matrix component, thus causing tissue damage in the pathological process [34]. Previous studies were largely focused on the BAL fluid level of MMPs (including MMP2, MMP8 and MMP9) and found an elevated expression pattern [35]. However, the circulating and BALF levels of MMP-1 (interstitial collagenase) and MMP-10 (Stromeolysin 2) in ARDS animals or patients are remained largely unknown. Collectively, we concluded a composite of plasma biomarkers with IL-1Ra, MMPs and ITIH4 may be useful to predict the severity of ARDS. Of course, this hypothesis needs further verification.

We also determined the role of HA330 cartridge-based HA on BALF and lung homogenate proteome (Additional file 8: Table S3, Additional file 9: Table S4, Additional file 10: Table S5, Additional file 11: Table S6). Notably, we found that the BALF level of secreted histone H2A, H2B and H4 was significantly blunted after HA therapy compared with HA-sham-treated pigs. Extracellular histones are the constituent of neutrophil extracellular traps (NETs) structures that ensnare and kill bacteria [36]. Elevated extracellular histones in BALF samples from humans with ARDS have been reported [37]. Also, instillation of neutralizing anti-histone H2A/H4 antibody reduced experimental ARDS severity [38]. Because extracellular histones origin from actively secretion by activated inflammatory cells, or from passively release by necrotic cells, we concluded that HA can significantly reduced the BALF level of histones by attenuating inflammatory lung injuries. BALF and lung level of Surfactant protein (SP)-B and SP-C were also significantly up-regulated by HA versus HA-sham treatment. Previous studies showed decreased levels of SP-A, SP-B and SP-C in BALF of ARDS patients [39]. Thus, HA treatment may improve oxygenation by restoring the alveolar levels of surfactant proteins. Collectively, we showed with the first experience that HA330-directed HA performance has a profound impact on plasma and lung proteome in a sepsis-induced ARDS porcine model.

Our studies have some strength. First, we comprehensively assessed the lung histologic features and other biomarkers when the ARDS model was initially diagnosed by oxygenation. Second, we first assessed the effect of HA on experimental ARDS model by using iTRAQ-labeled proteomic technology. However, our studies also have some limitations. This is a small sample animal study. Also, the effect of HA330 directed HA should be further tested by other ARDS models. Third, the experimental data cannot be directly introduced into the real clinical practice. There is still a long way to go that HA-330 cartridge-based HA can be used in ARDS patients.

Conclusions

In conclusion, HA330 resin-based HA attenuated experimental ARDS by blunting circulating and lung “cytokine storm,” improving permeability of alveolar barrier and promoting the recovery of the disordered proteomes.

Notes

Abbreviations

AaDO2 : 

Alveolar–arterial oxygen partial pressure difference

ARDS: 

Acute respiratory distress syndrome

CO: 

Cardiac output

CVVH: 

Continuous veno-venous hemofiltration

DAD: 

Diffuse alveolar damage

EBP: 

Extracorporeal blood purification

EVLW: 

Extravascular lung water

HA: 

Hemadsorption

H4, ITIH4: 

Inter-alpha-trypsin inhibitor heavy chain

IL-1Ra: 

Interleukin-1 receptor antagonist protein

PEEP: 

Positive end-expiratory pressure

MMP: 

Matrix metallopeptidase

MAP: 

Mean arterial pressure

MPAP: 

Mean pulmonary arterial pressure

NETs: 

Neutrophil extracellular traps

PVPI: 

Pulmonary vascular permeability index

PIM: 

Pulmonary intravascular macrophages

PVRI: 

Pulmonary vascular resistance index

SVRI: 

Systemic venous resistance index

Declarations

Authors’ contributions

XX designed, made, analyzed the experiments and drafted the manuscript. CJ designed and made the experiments. L Sa participated in the design and performance of the experiments. F Xiao, Y Li and H Dai participated in the analysis of the data and the critical revision of the article. C Wang contributed to the conception and design of the study, the analysis and interpretation of the data, revision of the article and final approval of the version to be published. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank Dr. Mingxu Shang, Dr. Hangyong He, Dr. Xiao Tang and Dr. Bing Sun, Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital for their for their excellent technical assistance.

Competing interests

The authors declare that they have no competing interests.

Availability of supporting data

All the data are available and will be submitted if required.

Consent for publication

All the coauthors approve the publication of this manuscript.

Ethical approval and consent to participate

This study was approved by the Institutional Animal Experiment Committee of Beijing Hospital.

Funding

This work was supported by Grants from National Natural Science Foundation of China (Nos. 81490534, 81490530, 81430001).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors’ Affiliations

(1)
National Clinical Research Centre for Respiratory Diseases, Beijing Hospital, Beijing, China
(2)
Department of Surgical Intensive Care Medicine, Beijing An Zhen Hospital, Capital Medical University, Beijing, China
(3)
Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China
(4)
Department of Pulmonary and Critical Care Medicine, Beijing Hospital, Beijing, China
(5)
Key Laboratory of Geriatrics, Beijing Hospital and Beijing Institute of Geriatrics, Ministry of Health, Beijing, China

References

  1. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1334–49.View ArticlePubMedGoogle Scholar
  2. Acute Respiratory Distress Syndrome Network, Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The acute respiratory distress syndrome network. N Engl J Med. 2000;342(18):1301–8.View ArticleGoogle Scholar
  3. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354(24):2564–75.View ArticlePubMedGoogle Scholar
  4. Villar J, Blanco J, Kacmarek RM. Current incidence and outcome of the acute respiratory distress syndrome. Curr Opin Crit Care. 2016;22(1):1–6.View ArticlePubMedGoogle Scholar
  5. Walter JM, Wilson J, Ware LB. Biomarkers in acute respiratory distress syndrome: from pathobiology to improving patient care. Expert Rev Respir Med. 2014;8(5):573–86.View ArticlePubMedGoogle Scholar
  6. Pierrakos C, Karanikolas M, Scolletta S, Karamouzos V, Velissaris D. Acute respiratory distress syndrome: pathophysiology and therapeutic options. J Clin Med Res. 2012;4(1):7–16.PubMedPubMed CentralGoogle Scholar
  7. Panagiotou A, Gaiao S, Cruz DN. Extracorporeal therapies in sepsis. J Intensive Care Med. 2013;28(5):281–95.View ArticlePubMedGoogle Scholar
  8. Su X, Bai C, Hong Q, Zhu D, He L, Wu J, et al. Effect of continuous hemofiltration on hemodynamics, lung inflammation and pulmonary edema in a canine model of acute lung injury. Intensive Care Med. 2003;29(11):2034–42.View ArticlePubMedGoogle Scholar
  9. Ullrich R, Roeder G, Lorber C, Quezado ZM, Kneifel W, Gasser H, et al. Continuous venovenous hemofiltration improves arterial oxygenation in endotoxin-induced lung injury in pigs. Anesthesiology. 2001;95(2):428–36.View ArticlePubMedGoogle Scholar
  10. Huang Z, Wang SR, Su W, Liu JY. Removal of humoral mediators and the effect on the survival of septic patients by hemoperfusion with neutral microporous resin column. Ther Apher Dial. 2010;14(6):596–602.View ArticlePubMedGoogle Scholar
  11. Kushi H, Miki T, Okamaoto K, Nakahara J, Saito T, Tanjoh K. Early hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation. Crit Care. 2005;9(6):R653–61.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Treml B, Neu N, Kleinsasser A, Gritsch C, Finsterwalder T, Geiger R, et al. Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets. Crit Care Med. 2010;38(2):596–601.View ArticlePubMedGoogle Scholar
  13. Nieman GF, Gatto LA, Paskanik AM, Yang B, Fluck R, Picone A. Surfactant replacement in the treatment of sepsis-induced adult respiratory distress syndrome in pigs. Crit Care Med. 1996;24(6):1025–33.View ArticlePubMedGoogle Scholar
  14. Matute-Bello G, Downey G, Moore BB, Groshong SD, Matthay MA, Slutsky AS, et al. An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. Am J Respir Cell Mol Biol. 2011;44(5):725–38.View ArticlePubMedGoogle Scholar
  15. Conesa A, Gotz S, Garcia-Gomez JM, Terol J, Talon M, Robles M. Blast2GO: a universal tool for annotation, visualization and analysis in functional genomics research. Bioinformatics. 2005;21(18):3674–6.View ArticlePubMedGoogle Scholar
  16. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Ballard-Croft C, Wang D, Sumpter LR, Zhou X, Zwischenberger JB. Large-animal models of acute respiratory distress syndrome. Ann Thorac Surg. 2012;93(4):1331–9.View ArticlePubMedGoogle Scholar
  18. Mutz C, Mirakaj V, Vagts DA, Westermann P, Waibler K, Konig K, et al. The neuronal guidance protein netrin-1 reduces alveolar inflammation in a porcine model of acute lung injury. Crit Care. 2010;14(5):R189.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Matute-Bello G, Frevert CW, Martin TR. Animal models of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2008;295(3):L379–99.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Albertini M, Clement MG, Lafortuna CL, Caniatti M, Magder S, Abdulmalek K, et al. Role of poly-(ADP-ribose) synthetase in lipopolysaccharide-induced vascular failure and acute lung injury in pigs. J Crit Care. 2000;15(2):73–83.View ArticlePubMedGoogle Scholar
  21. Guo ZL, Lu GP, Ren T, Zheng YH, Gong JY, Yu J, et al. Partial liquid ventilation confers protection against acute lung injury induced by endotoxin in juvenile piglets. Respir Physiol Neurobiol. 2009;167(3):221–6.View ArticlePubMedGoogle Scholar
  22. McVerry BJ, Peng X, Hassoun PM, Sammani S, Simon BA, Garcia JG. Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury. Am J Respir Crit Care Med. 2004;170(9):987–93.View ArticlePubMedGoogle Scholar
  23. Jozwiak M, Teboul JL, Monnet X. Extravascular lung water in critical care: recent advances and clinical applications. Ann Intensive Care. 2015;5(1):38.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Kushimoto S, Taira Y, Kitazawa Y, Okuchi K, Sakamoto T, Ishikura H, et al. The clinical usefulness of extravascular lung water and pulmonary vascular permeability index to diagnose and characterize pulmonary edema: a prospective multicenter study on the quantitative differential diagnostic definition for acute lung injury/acute respiratory distress syndrome. Crit Care. 2012;16(6):R232.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301(23):2445–52.View ArticlePubMedGoogle Scholar
  26. Rimmele T, Kellum JA. Clinical review: blood purification for sepsis. Crit Care. 2011;15(1):205.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Mikacenic C, Hansen EE, Radella F, Gharib SA, Stapleton RD, Wurfel MM. Interleukin-17A is associated with alveolar inflammation and poor outcomes in acute respiratory distress syndrome. Crit Care Med. 2016;44(3):496–502.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Huang Z, Wang SR, Yang ZL, Liu JY. Effect on extrapulmonary sepsis-induced acute lung injury by hemoperfusion with neutral microporous resin column. Ther Apher Dial. 2013;17(4):454–61.View ArticlePubMedGoogle Scholar
  29. Palomo J, Dietrich D, Martin P, Palmer G, Gabay C. The interleukin (IL)-1 cytokine family—balance between agonists and antagonists in inflammatory diseases. Cytokine. 2015;76(1):25–37.View ArticlePubMedGoogle Scholar
  30. Parsons PE, Moss M, Vannice JL, Moore EE, Moore FA, Repine JE. Circulating IL-1ra and IL-10 levels are increased but do not predict the development of acute respiratory distress syndrome in at-risk patients. Am J Respir Crit Care Med. 1997;155(4):1469–73.View ArticlePubMedGoogle Scholar
  31. Rogy MA, Coyle SM, Oldenburg HS, Rock CS, Barie PS, Van Zee KJ, et al. Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J Am Coll Surg. 1994;178(2):132–8.PubMedGoogle Scholar
  32. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16–32.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Gonzalez-Ramon N, Hoebe K, Alava MA, Van Leengoed L, Pineiro M, Carmona S, et al. Pig MAP/ITIH4 and haptoglobin are interleukin-6-dependent acute-phase plasma proteins in porcine primary cultured hepatocytes. Eur J Biochem. 2000;267(6):1878–85.View ArticlePubMedGoogle Scholar
  34. Rydlova M, Holubec L Jr, Ludvikova M Jr, Kalfert D, Franekova J, Povysil C, et al. Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Res. 2008;28(2B):1389–97.PubMedGoogle Scholar
  35. Davey A, McAuley DF, O’Kane CM. Matrix metalloproteinases in acute lung injury: mediators of injury and drivers of repair. Eur Respir J. 2011;38(4):959–70.View ArticlePubMedGoogle Scholar
  36. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–5.View ArticlePubMedGoogle Scholar
  37. Abrams ST, Zhang N, Manson J, Liu T, Dart C, Baluwa F, et al. Circulating histones are mediators of trauma-associated lung injury. Am J Respir Crit Care Med. 2013;187(2):160–9.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Bosmann M, Grailer JJ, Ruemmler R, Russkamp NF, Zetoune FS, Sarma JV, et al. Extracellular histones are essential effectors of C5aR- and C5L2-mediated tissue damage and inflammation in acute lung injury. FASEB J. 2013;27(12):5010–21.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Bhargava M, Wendt CH. Biomarkers in acute lung injury. Transl Res. 2012;159(4):205–17.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s) 2017

Advertisement